Search results for "lung cancer"

showing 10 items of 508 documents

The role of second and third line tyrosine kinase inhibitor monotherapy in EGFR wild-type (and unknown mutational status) advanced non-small-cell lun…

2015

Oncologymedicine.medical_specialtybusiness.industrymedicine.drug_classWild typeHematologymedicine.diseaseTyrosine-kinase inhibitorOncologyThird lineInternal medicinemedicineRetrospective analysisMutational statusNon small cellbusinessLung cancerAnnals of Oncology
researchProduct

Global and sex-specific epigenome-wide association studies for the identification of the main methylated loci related to smoking in a mediterranean p…

2019

Abstract Background Tobacco use has been reported to be the main cause of 90% of male and 80% of female lung cancers, as well as a relevant risk factor for other cancers such as oropharynx, larynx, esophagus, stomach, liver, pancreas, kidney, bladder, and colorectum. Smoking directly affects DNA methylation and although several genes have been reported to be differentially methylated in smokers, gender differences and population-specific differences remain to be further investigated. Our aim was to undertake global and sex-specific genome-wide epigenomic studies (EWAS) in a Mediterranean population to identify the main smoking DNA-methylated genes. Methods We analyzed 88 participants in the…

Oncologymedicine.medical_specialtyeducation.field_of_studybusiness.industryPopulationAryl hydrocarbon receptor repressorHematologyMethylationmedicine.diseaseF2RL3OncologyCpG siteInternal medicineDNA methylationmedicineLung cancereducationbusinessEpigenomicsAnnals of Oncology
researchProduct

Central Nervous System Malignancies

2021

The primitive neoplasms of the central nervous system (CNS) are a rare and heterogeneous group of malignancies. Brain metastases (BMs) are the most frequent intracranial tumor, and their incidence is rising in the last few decades. Primary tumors more often complicated by BMs are lung cancer, breast cancer, and melanoma. Neuroimaging techniques, mainly magnetic resonance imaging (MRI), play a key role for the diagnosis of BMs. The management of BMs is based on a multimodal approach, including symptomatic treatment, local treatment, such as surgery, stereotactic radiosurgery (SRS), and whole brain radiotherapy (WBRT), and systemic therapy, such as chemotherapy, target therapy, or immunothera…

Oncologymedicine.medical_specialtymedicine.diagnostic_testbusiness.industrymedicine.medical_treatmentMelanomaeducationdigestive oral and skin physiologyMultimodal therapyMagnetic resonance imagingmedicine.diseaseRadiosurgeryRadiation therapystomatognathic diseasesBreast cancerInternal medicinemedicineNeurosurgeryLung cancerbusiness
researchProduct

Is there any place for PD-1/CTLA-4 inhibitors combination in the first-line treatment of advanced NSCLC?—A trial-level meta-analysis in PD-L1 selecte…

2021

BACKGROUND: The advent of immuno-oncology (IO) represented a breakthrough in non-small cell lung cancer (NSCLC) therapy over the last few years. However, establishing the optimal therapeutic options among programmed death-ligand 1 (PD-L1) selected subgroups still addresses an unmet need in the clinical setting. METHODS: We performed a systematic review and finally included eleven first-line randomized controlled trials to compare efficacy and safety outcomes among first-line IO treatment strategies versus standard platinum-based chemotherapy (CT) according to PD-L1 expression level (<1%, 1–49%, ≥50%). Pooled hazard ratios (HRs) and risk ratios (RRs) for progression-free survival (PFS), over…

Oncologymedicine.medical_specialtyprogrammed death-1/cytotoxic T-lymphocyte antigen 4 inhibitors (PD-1/CTLA-4 inhibitors)combined modality therapybusiness.industryHazard ratioCombined modality therapy; Immunotherapy; Meta-analysis; Non-small cell lung cancer (NSCLC); Programmed death-1/cytotoxic T-lymphocyte antigen 4 inhibitors (PD-1/CTLA-4 inhibitors)non-small cell lung cancer (NSCLC)Non-small cell lung cancer (NSCLC)medicine.diseaselaw.inventionDiscontinuationmeta-analysisOncologyRandomized controlled triallawRelative riskInternal medicineMeta-analysisMedicineOriginal ArticleimmunotherapybusinessLung cancerAdverse effect
researchProduct

Tea Consumption and Risk of Cancer

2020

Tea is one of the most widely consumed beverages, but its association with cancer risk remains controversial and unclear. We performed an umbrella review to clarify and determine the associations between tea consumption and various types of cancer by summarizing and recalculating the existing meta-analyses. Meta-analyses of observational studies reporting associations between tea consumption and cancer risk were searched on PubMed and Embase. Associations found to be statistically significant were further classified into levels of evidence (convincing, suggestive, or weak), based on P value, between-study heterogeneity, prediction intervals, and small study effects. Sixty-four observational…

Oncologymedicine.medical_specialtyteaMedicine (miscellaneous)Review03 medical and health sciences0302 clinical medicineBreast cancerInternal medicinemedicinecancer030212 general & internal medicineLung cancerProspective cohort studyThyroid cancercancer meta-analysis oral cancer tea umbrella reviewNutrition and Dieteticsumbrella reviewbusiness.industrymeta-analysis oral cancer umbrella review Feeding Behavior Humans Incidence Observational Studies as Topic Prospective Studies Risk Factors Neoplasms TeaCanceroral cancermedicine.diseasemeta-analysis030220 oncology & carcinogenesisMeta-analysisOvarian cancerLiver cancerbusinessFood ScienceAdvances in Nutrition
researchProduct

Neoadjuvant chemotherapy for stage IIIA-N2 non-small cell lung cancer

2005

Neoadjuvant chemotherapy in potentially resectable stage IIIA-N2 non-small cell lung cancer (NSCLC) has become standard of treatment in the last years. Two randomised pioneer phase III trials conducted with second generation platinum combinations had demonstrated an advantage in survival of induction chemotherapy followed by surgery versus surgery alone. Subsequently, a wide number of phase II studies with third generation platinum-based doublets or triplets have increased the evidence of the activity as well as the good tolerability of this approach. Nowadays, the main topics of ongoing clinical research are to assess the role of induction chemotherapy in early stage disease, and the role …

Oncologystage IIIA-N2medicine.medical_specialtyLung NeoplasmsPaclitaxelmedicine.medical_treatmentDocetaxelNSCLCDeoxycytidinemolecular markers analysisCarcinoma Non-Small-Cell LungInternal medicineAntineoplastic Combined Chemotherapy ProtocolsHumansMedicineStage (cooking)Lung cancerNeoplasm StagingCisplatinChemotherapybusiness.industryInduction chemotherapyHematologymedicine.diseaseearly stageGemcitabineRadiation therapyneoadjuvant radiotherapyOncologyTolerabilityDocetaxelChemotherapy AdjuvantRadiotherapy AdjuvantTaxoidsCisplatinbusinessmedicine.drugneoadjuvant chemotherapy
researchProduct

“Comparison of the safety and efficacy of paclitaxel plus gemcitabine combination in young and elderly patients with locally advanced or metastatic n…

2008

We retrospectively assessed tolerability and efficacy of paclitaxel plus gemcitabine combination in 259 patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) enrolled in three randomized SICOG trials according to their age (70 years) at study entry. Apart from age, demographic and clinical characteristics were similar in the two groups. Response rate of paclitaxel plus gemcitabine was similar in younger and in elderly (36% versus 30%). Chemotherapy was well tolerated, but severe neutropenia (12% versus 7%), anaemia (6.6% versus 1.8%), and vomiting (5% versus 0) were more frequent in elderly patients. Both median progression-free survival (PFS, 5.5 months versus 4.2…

PaclitaxelNon-small cell lung cancerGemcitabineElderly patient
researchProduct

Interstitial lung disease associated with drug therapy

2004

Drug-associated interstitial lung disease (ILD) is not uncommon, with diverse patterns ranging from benign infiltrates to the potentially fatal acute respiratory distress syndrome. As acute respiratory failure due to drug-associated ILD has an unpredictable onset and rapid time course, establishing a diagnosis is often difficult. An accurate diagnosis is based on clinical, radiological (including high-resolution computed tomography) and histological manifestations, although is often only possible by exclusion. Cancer chemotherapy is commonly associated with acute disease that, on pathology, is often diffuse alveolar damage. Furthermore, a combination of drugs with or without radiotherapy ca…

PaperCancer Researchmedicine.medical_specialtyPathologyAntimetabolites AntineoplasticLung Neoplasmsmedicine.medical_treatmentDiseaseNSCLCchemotherapybehavioral disciplines and activitiesPharmacotherapyGefitinibJapanRisk FactorsCarcinoma Non-Small-Cell LungEpidemiologyAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansIntensive care medicineDiffuse alveolar damageLung cancerAgedinterstitial lung diseaseAged 80 and overRespiratory Distress Syndromegefitinib (‘Iressa’)business.industryInterstitial lung diseaseGefitinibrespiratory systemMiddle Agedmedicine.diseaserespiratory tract diseasesRadiation therapyOncologyQuinazolinesOral PresentationbusinessLung Diseases Interstitialmedicine.drugBritish Journal of Cancer
researchProduct

Parathyroid hormone-related protein (PTHrP)-dependent modulation of gene expression signatures in cancer cells

2022

PTHrP is encoded by PTHLH gene which can generate by alternative promoter usage and splicing mechanisms at least three mature peptides of 139, 141 and 173 amino acids with distinct carboxy terminus. PTHrP may undergo proteolytic processing into smaller bioactive forms, comprising an amino terminus peptide, which is the mediator of the "classical" PTH-like effect, as well as midregion and carboxy terminus peptides that act as multifaceted critical regulator of proliferation, differentiation and apoptosis via the reprogramming of gene expression in normal and neoplastic cells. Moreover, a nuclear/nucleolar localization signal sequence is present in the [87-107] domain allowing PTHrP nuclear i…

Parathyroid HormoneNeoplasmsParathyroid Hormone-Related ProteinHumansApoptosisSettore BIO/06 - Anatomia Comparata E CitologiaPeptidesTranscriptomeGene signatures Bone tumor Breast tumor Gastrointestinal tumor Prostate tumor Lung cancer Leukemia/lymphoma
researchProduct

Antiamphiphysin-positive stiff-person syndrome associated with small cell lung cancer

2006

The paraneoplastic amphiphysin(+) stiff-person syndrome (SPS) has so far only been described in women with breast adenocarcinoma. Here, we describe the rare case of a female patient with antiamphiphysin(+) SPS due to small cell cancer of the lung.

Pathologymedicine.medical_specialtyLung NeoplasmseducationNerve Tissue ProteinsStiff-Person SyndromeBreast AdenocarcinomaSmall-cell carcinomafluids and secretionsmedicineCarcinomaHumansCarcinoma Small CellLung cancerAutoantibodiesLungElectromyographybusiness.industryfungiRespiratory diseaseMiddle Agedequipment and suppliesmedicine.diseasemedicine.anatomical_structureNeurologyAmphiphysinFemaleNeurology (clinical)businessStiff person syndromeMovement Disorders
researchProduct